Novavax and its partner Serum Institute of India announced on Monday that their COVID-19 vaccine has acquired emergency use authorization in Indonesia, marking the company's first approval anywhere in the globe.

Novavax's stock jumped about 11% before the market opened after the firm said that it has submitted an application for emergency use of the vaccine to Canada and the European Medicines Agency.

The vaccine will be produced by Serum Institute, the world's largest vaccine manufacturer, and distributed under the Covovax brand name in Indonesia. Initial shipments to Indonesia are scheduled to begin soon, according to Novavax.

According to the government, the country will receive 20 million doses of the protein-based vaccine this year.

Coronavirus Vaccine Updates | COVID-19 Vaccine Latest News | Novavax

Penny Lukito, the head of Indonesia's National Agency for Drug and Food Control, did not immediately respond to a request for comment from Reuters. Novavax has requested European Union approval in a number of countries, including the United Kingdom, Australia, India, and the Philippines. On Friday, the firm announced that it was prepared to seek regulatory clearance for a rollout in Japan early next year, in collaboration with its Japanese partner Takeda Pharmaceutical.

Novavax and Serum Institute have agreed to give more than 1.1 billion doses to the World Health Organization-led COVAX facility. After obtaining an emergency use listing from the WHO, the vaccine will be available this year and will last until 2022.

Novavax has postponed its application for US approval until the end of the year, and Politico reported last month that the business is experiencing production and quality issues.

In a large, late-stage clinical trial in the United States, the Novavax shot was proven to be more than 90% effective, including against a number of worrying coronavirus types.